Abstract:AIMS:We conducted a presentation on an 84-year-old male patient who has been diagnosed with TTRA81V (p. TTRA101V) hereditary transthyretin cardiac amyloidosis (hATTR-CM). In order to establish its pathogenicity, we extensively investigated the biochemical and biophysical properties of the condition. METHODS AND RESULTS:Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly acknowledged progressive infiltrative cardiomyopathy that leads to heart failure and potentially fatal arrhythmias. Gaining a comprehensive understanding of the biochemical and biophysical characteristics of genetically mutated TTR proteins serves as the fundamental cornerstone for delivering precise medical care to individuals affected by ATTR. Laboratory assessments indicated a brain natriuretic peptide of 200.12 ng/L (normal range: 0-100 ng/L) and high-sensitivity cardiac troponin I of 0.189 μg/L (normal range: 0-0.1 μg/L). Echocardiography identified left atrial enlargement, symmetrical left ventricular hypertrophy (16 mm septal and 16 mm posterior wall), and a left ventricular ejection fraction of 56%. Cardiac-enhanced magnetic resonance imaging revealed subendocardial late gadolinium enhancement. Tc-99m-PYP nuclear scintigraphy confirmed grade 3 myocardial uptake, showing an increased heart-to-contralateral ratio (H/CL = 2.33). Genetic testing revealed a heterozygous missense mutation in the TTR gene (c.302C>T), resulting in an alanine-to-valine residue change (p. Ala81Val, following the first 20 residues of signal sequence nomenclature). Biochemical analysis of this variant displayed compromised kinetic stability in both the TTRA81V:WT (wild-type) heterozygote protein (half-life, t1/2 = 21 h) and the TTRA81V homozygote protein (t1/2 = 17.5 h). The kinetic stability fell between that of the TTRWT (t1/2 = 42 h) and the early-onset TTRL55P mutation (t1/2 = 4.4 h), indicating the patient's late-onset condition. Kinetic stabilizers (Tafamidis, Diflunisal, and AG10) all exhibited the capacity to inhibit TTRA81V acid- and mechanical force-induced fibril formation, albeit less effectively than with TTRWT. Chromatographic assessment of the patient's serum TTR tetramers indicated a slightly lower concentration (3.0 μM) before oral administration of Tafamidis compared with the normal range (3.6-7.2 μM). CONCLUSIONS:We identified a patient with hATTR-CM who possesses a rare TTRA81V mutation solely associated with cardiac complications. The slightly reduced kinetic stability of this mutation indicates its late-onset nature and contributes to the gradual progression of the disease.

Abstract 11641: The Role of Inflammation in a Humanized Mouse Model of Transthyretin Cardiac Amyloidosis

Human in vitro disease modeling of ATTR cardiac amyloidosis

Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy

Abstract 18660: A Potential Role of TRPM2 Mediated Inflammation in Heart Disease

Engineering hiPSC-derived tissue models for advanced amyloidosis research and therapy development

Vitronectin promotes TTR deposition and mitochondrial damage in ATTR-CA mice

A mouse model of cardiac AL amyloidosis unveils mechanisms of tissue accumulation and toxicity of amyloid fibrils

Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression

Biochemical and Biophysical Properties of an Unreported T96R Mutation Causing Transthyretin Cardiac Amyloidosis

Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells

Single-Cell RNA Sequencing to Dissect the Immunological Network of Autoimmune Myocarditis

Gene expression profiling during the transition to failure in TNF-alpha over-expressing mice demonstrates the development of autoimmune myocarditis.

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

Inconsistency Between Hepatic Expression and Serum Concentration of Transthyretin in Mice Humanized at the Transthyretin Locus.

Abstract 14427: Differences in Molecular Phenotype in Mouse and Human Hypertrophic Cardiomyopathy Suggest Need for Precision Medicine Approach to Treatment Based on Human Studies

Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition

Abstract 5501: Reduced Coronary Reserve As a Mechanism in Beta-Adrenergic Receptor Mediated Cardiomyopathy and Its Rescue by Adenylyl Cyclase Type 5 Knockout

Inflammatory Crosstalk Impairs Phagocytic Receptors and Aggravates Atherosclerosis in Clonal Hematopoiesis in Mice

Biochemical and Biophysical Properties of a Rare TTRA81V Mutation Causing Mild Transthyretin Amyloid Cardiomyopathy

Current Evidence Supporting the Role of Immune Response in ATTRv Amyloidosis

META-ANALYSES ON DOUBLE-BLIND RCTS ADDING DRUGS WITH ANTI-INFLAMMATORY PROPERTIES TO ANTIPSYCHOTIC MEDICATION